CV Sciences (CVSI) Other Accumulated Expenses (2013 - 2026)
CV Sciences (CVSI) reported Other Accumulated Expenses of $1.1 million for Q1 2026, down 24.9% on a YoY basis from $1.5 million in Q1 2025, and up 1.76% sequentially from $1.1 million in Q4 2025.
CV Sciences (CVSI) Other Accumulated Expenses (2013 - 2026) Analysis & Trends
CV Sciences (CVSI) has 11 years of Other Accumulated Expenses data on file, last reported at $1.1 million in Q1 2026.
- For the quarter ending Q1 2026, Other Accumulated Expenses fell 24.9% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $1.1 million (down 24.9% YoY), and the FY2025 full-year result was $1.1 million, down 23.96% from the prior year.
- Other Accumulated Expenses grew to $1.1 million in Q1 2026, from $1.1 million in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $1.6 million in Q2 2025 to a low of $1.1 million in Q4 2025.
- A 5-year average of $1.4 million and a median of $1.5 million in 2024 frame the typical range for Other Accumulated Expenses.
- Across the five-year window, Other Accumulated Expenses increased 6.85% in 2025 and slipped 24.9% in 2026, its largest moves.
- Tracing CVSI's Other Accumulated Expenses over 5 years: stood at $1.5 million in 2022, then dropped by 2.39% to $1.5 million in 2023, then dropped by 5.89% to $1.4 million in 2024, then slipped by 23.96% to $1.1 million in 2025, then grew by 1.76% to $1.1 million in 2026.
- Business Quant data shows CVSI's Other Accumulated Expenses at $1.1 million in Q1 2026, $1.1 million in Q4 2025, and $1.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | CV Sciences | 3.74 Mn | 3.43 Mn | 1.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.10 Mn |
| Dec 31, 2025 | 1.08 Mn |
| Sep 30, 2025 | 1.50 Mn |
| Jun 30, 2025 | 1.57 Mn |
| Mar 31, 2025 | 1.47 Mn |
| Dec 31, 2024 | 1.42 Mn |
| Sep 30, 2024 | 1.49 Mn |
| Jun 30, 2024 | 1.51 Mn |
| Mar 31, 2024 | 1.37 Mn |
| Dec 31, 2023 | 1.51 Mn |
| Dec 31, 2022 | 1.55 Mn |
| Sep 30, 2018 | 900,555.00 |
| Jun 30, 2018 | 1.11 Mn |
| Mar 31, 2018 | 534,627.00 |
| Dec 31, 2017 | 894,798.00 |
| Sep 30, 2017 | 232,622.00 |
| Jun 30, 2017 | 278,207.00 |
| Mar 31, 2017 | 2.43 Mn |
| Dec 31, 2016 | 170,092.00 |
| Sep 30, 2016 | 147,308.00 |